Loading clinical trials...
Loading clinical trials...
This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastro...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ironwood Pharmaceuticals, Inc.
NCT02616302 · Gastroesophageal Reflux Disease (GERD)
NCT05132816 · Gastroesophageal Reflux, Esophageal Motility Disorders, and more
NCT06926374 · Colorectal Carcinoma, Rectal Prolapse, and more
NCT00590239 · Barrett's Esophagus, Neoplasms, and more
NCT04506593 · Eosinophilic Esophagitis, Gastroesophageal Reflux Disease (GERD), and more
Ironwood Investigational Site
North Little Rock, Arkansas
Ironwood Investigational Site
Anaheim, California
Ironwood Investigational Site
Monroe, Louisiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions